Valeant Pharmaceutics to spend $1billion to buy Addyi
Valeant Pharmaceutics will pay about $1 billion to buy the female Viagra, Addyi from Sprout Pharmaceuticals
Valeant Pharmaceuticals has recently announced a buy-out deal of $1 billion with Sprout Pharmaceuticals, after the latter got the approval from US regulators for first prescription drug intended to boost sexual desire in women. The Sprout pill is called Addyi, and is expected to be available in the US market in the fourth quarter. This deal between the two pharmaceutical giants is expected to be closed this quarter.
Valeant plans to pay about $500 million at closing for Raleigh, North Carolina-based Sprout. The Canadian drugmaker will then make another milestone-based payment of around $500 million in the first quarter of next year, as reported by AP.
Valeant Pharmaceuticals has recently announced a buy-out deal of $1 billion with Sprout Pharmaceuticals, after the latter got the approval from US regulators for first prescription drug intended to boost sexual desire in women. The Sprout pill is called Addyi, and is expected to be available in the US market in the fourth quarter. This deal between the two pharmaceutical giants is expected to be closed this quarter.
Valeant plans to pay about $500 million at closing for Raleigh, North Carolina-based Sprout. The Canadian drugmaker will then make another milestone-based payment of around $500 million in the first quarter of next year, as reported by AP.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.